标靶药物传输市场：依疾病类型、应用、最终用户和地区划分

2025 年全球标靶药物传输市场规模预估为 107.2 亿美元，预计到 2032 年将达到 308.8 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 16.3%。

数字。 2025 年标靶药物传输市场占有率（%）（按地区划分）

标靶药物传输是指将药物化合物直接输送到体内的作用目标部位，最大限度地提高治疗效果，并最大限度地减少副作用。这涉及将药物与识别特定细胞表面受体或抗原的靶向配体或部分封装或结合。这使得药物载体系统能够选择性地针对体内患病细胞或组织，增加药物在作用部位的生物生物有效性并减少全身副作用。标靶药物传输可使药物在特异性部位发挥作用，因此对于有效管理各种慢性疾病（包括癌症、心血管疾病和神经系统疾病）具有巨大潜力。

市场动态：

标靶药物传输市场主要受全球慢性病盛行率上升、对疗效优异、安全性高的精准药物的需求增加、以及製药公司对先进药物输送技术研发投入增加的推动。此外，老年人口的增加更容易患慢性病，对奈米药物和标靶治疗的持续研究以及新型标靶药物製剂的监管核准，都是为市场参与者创造丰厚机会的主要因素。然而，标靶给药系统的高开发成本、新兴国家缺乏适当的临床研究基础设施以及标靶药物配方的复杂性是限制其快速应用的主要挑战。行业专家和研究人员为开发经济实惠且稳定的标靶递送解决方案所做的各种努力可能会在未来几年有助于克服这些限制。

本研究的主要特点

• 本报告对全球标靶药物传输市场进行了详细分析，并提供了预测期（2025-2032）的市场规模（十亿美元）和复合年增长率（CAGR%），假设 2024 年为基准年。
• 它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球标靶药物传输市场的主要企业是根据公司亮点、产品系列、关键亮点、业绩和策略等参数列出的。
• 本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
• 全球药物输送市场迎合了该行业的各种相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过用于分析全球标靶药物传输市场的各种策略矩阵来简化决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管情景
• 製造商收益
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球标靶药物传输市场-冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020 年至 2032 年按疾病类型分類的全球标靶药物传输市场（十亿美元）

• 心血管疾病
• 肺部疾病
• 感染疾病
• 内分泌失调
• 肿瘤疾病

6. 2020 年至 2032 年全球标靶药物传输市场（按应用划分）（十亿美元）

• 主要目标
• 次要目标
• 第三目标

7. 2020 年至 2032 年全球标靶药物传输市场（按最终用户划分）（十亿美元）

• 医院
• 诊所
• 其他的

8. 2020 年至 2032 年全球标靶药物传输市场（按地区划分）（十亿美元）

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • AbbVie Inc.
  • Sanofi
  • Arrowhead Pharmaceuticals, Inc.
  • Baxter International Inc.
  • AstraZeneca
  • Boston Scientific Corporation
  • Depomed, Inc.
  • Fraunhofer Gesellschaft Munchen
  • Janssen Global Services, LLC
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

第 10 章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Targeted Drug Delivery Market is estimated to be valued at USD 10.72 Bn in 2025 and is expected to reach USD 30.88 Bn by 2032, growing at a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032.

Figure. Targeted Drug Delivery Market Share (%), By Region 2025

Targeted drug delivery refers to the delivery of pharmaceutical compounds directly to the targeted sites of action in the body, thus maximizing the therapeutic effects and minimizing the side effects. It involves the encapsulation or conjugation of drugs with targeting ligands or moieties that recognize specific cell-surface receptors or antigens. This allows the drug carrier system to selectively target the diseased cells or tissues in the body, thereby increasing the bioavailability of drugs at the site of action and reducing systemic side effects. Targeted drug delivery holds tremendous potential for the effective management of various chronic diseases like cancer, cardiovascular ailments, neurological disorders, etc. as it allows site-specific action of drugs.

Market Dynamics:

The targeted drug delivery market is primarily driven by the rising prevalence of chronic diseases globally, boosting the demand for precision medicines with superior efficacy and safety profiles, increasing R&D investments by pharmaceutical companies in advanced drug delivery technologies. Furthermore, the growing geriatric population susceptible to chronic health conditions, ongoing research on nanomedicines and targeted therapies, and regulatory approvals of novel targeted drug formulations are some key factors creating lucrative opportunities for market players. However, high development costs associated with targeted delivery systems, lack of proper infrastructure for clinical research in emerging nations, and complexity of targeted drug formulations are major challenges restraining the rapid adoption. Various initiatives by industry experts and researchers to develop affordable and stable targeted delivery solutions can help overcome these limitations in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global targeted drug delivery market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global targeted drug delivery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes AbbVie Inc., Sanofi , Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca , Boston Scientific Corporation, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC, Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Taiwan Liposome Company, Ltd., and Vectura Group PLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global targeted drug delivery market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global targeted drug delivery market.

Detailed Segmentation-

• By Disease Type:
  • Cardiovascular Diseases
  • Pulmonary Diseases
  • Infectious Diseases
  • Endocrine Diseases
  • Oncological Disorders
• By Application:
  • First Order Targeting
  • Second Order Targeting
  • Third Order Targeting
• By End User:
  • Hospitals
  • Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Sanofi
  • Arrowhead Pharmaceuticals, Inc.
  • Baxter International Inc.
  • AstraZeneca
  • Boston Scientific Corporation
  • Depomed, Inc.
  • Fraunhofer Gesellschaft Munchen
  • Janssen Global Services, LLC
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Targeted Drug Delivery Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Targeted Drug Delivery Market, By Disease Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Cardiovascular Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pulmonary Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Infectious Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Endocrine Diseases
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncological Disorders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Targeted Drug Delivery Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• First Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Second Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Third Order Targeting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Targeted Drug Delivery Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Targeted Drug Delivery Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AbbVie Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Arrowhead Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Baxter International Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Boston Scientific Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Depomed, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Fraunhofer Gesellschaft Munchen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Janssen Global Services, LLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Luye Pharma Group
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Savara Inc.
  • Roche Holding AG
  • Suda Limited
  • Taiwan Liposome Company, Ltd.
  • Vectura Group PLC

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact